- Home
- GLPG vs PACS Comparison
GLPG vs PACS Comparison
Compare GLPG & PACS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- PACS
- Stock Information
- Founded
- GLPG 1999
- PACS 2013
- Country
- GLPG Belgium
- PACS United States
- Employees
- GLPG N/A
- PACS N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- PACS
- Sector
- GLPG Health Care
- PACS
- Exchange
- GLPG Nasdaq
- PACS Nasdaq
- Market Cap
- GLPG 2.1B
- PACS 2.1B
- IPO Year
- GLPG 2005
- PACS 2024
- Fundamental
- Price
- GLPG $29.89
- PACS $12.84
- Analyst Decision
- GLPG Hold
- PACS Buy
- Analyst Count
- GLPG 4
- PACS 4
- Target Price
- GLPG $30.00
- PACS $26.25
- AVG Volume (30 Days)
- GLPG 209.6K
- PACS 571.1K
- Earning Date
- GLPG 11-05-2025
- PACS 11-07-2025
- Dividend Yield
- GLPG N/A
- PACS N/A
- EPS Growth
- GLPG N/A
- PACS 82.80
- EPS
- GLPG N/A
- PACS 0.68
- Revenue
- GLPG $323,674,692.00
- PACS $3,558,953,000.00
- Revenue This Year
- GLPG $1.77
- PACS $28.62
- Revenue Next Year
- GLPG $0.44
- PACS $16.94
- P/E Ratio
- GLPG N/A
- PACS $18.86
- Revenue Growth
- GLPG 5.43
- PACS 205.08
- 52 Week Low
- GLPG $22.36
- PACS $7.50
- 52 Week High
- GLPG $37.78
- PACS $32.10
- Technical
- Relative Strength Index (RSI)
- GLPG 34.46
- PACS 54.58
- Support Level
- GLPG $30.92
- PACS $11.55
- Resistance Level
- GLPG $31.85
- PACS $12.82
- Average True Range (ATR)
- GLPG 0.81
- PACS 0.58
- MACD
- GLPG -0.27
- PACS -0.04
- Stochastic Oscillator
- GLPG 1.70
- PACS 63.86
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About PACS PACS Group Inc. Common Stock
PACS Group Inc is a post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.